Idorsia

Idorsia, founded in 2017, is a biopharmaceutical company specializing in the discovery and development of small molecules. Headquartered in Switzerland, the company's core mission is to transform therapeutic options by bringing innovative medicines to patients. Idorsia operates within the Pharmaceuticals and Healthcare industries, focusing on creating a broad portfolio of novel drugs. Its strategic approach emphasizes robust research and development capabilities, aiming to address unmet medical needs across various therapeutic areas. The company's commitment to scientific advancement is central to its operational philosophy.

With a dedicated research center, Idorsia employs a workforce ranging from 500 - 1,000 employees, contributing to its operational scale and innovation capacity. The company's structure supports the complex process of drug discovery through to commercialization. Idorsia's operational footprint, while centered in Switzerland, aims to impact global health outcomes. Understanding the human capital behind its scientific endeavors is key; one can learn more about the individuals driving its progress by visiting Meet Idorsia's team. This focus on talent and operational excellence underpins its pursuit of groundbreaking pharmaceutical solutions.

Financially, Idorsia reported a revenue of $293.8M. The company has secured significant funding, including debt and stock issuances, to fuel its extensive pipeline and development programs. These financial resources are critical for advancing its portfolio of innovative drugs from discovery to market. Idorsia's strategic financial management supports its long-term vision of delivering new therapeutic options. For a detailed overview of its financial performance and investment history, interested parties can Explore financial highlights. The company's product development centers on small molecule drugsView more...